{
    "nctId": "NCT00027807",
    "briefTitle": "Biological Therapy in Treating Women With Stage IV Breast Cancer",
    "officialTitle": "Treatment of Stage IV Breast Cancer With OKT3 x Herceptin Armed Activated T Cells, Low Dose IL-2, And GM-CSF (Phase I Only as of 4-22-09 as Per IRB Approval Date)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 6,
    "primaryOutcomeMeasure": "Maximum tolerated dose",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nPhase I:\n\n* Histologically confirmed infiltrating ductal carcinoma of the breast\n* Metastatic disease\n\n  * Clinically asymptomatic with non-life-threatening metastases allowed\n* Measurable or evaluable disease by radiograph, CT scan, MRI, nuclear medicine bone scan, or physical examination\n\n  * No measurable disease allowed if tumor or metastasis has been removed or successfully treated prior to study\n* No rapidly progressive symptomatic disease affecting major organ systems (e.g., lungs and liver)\n* Stable or unstable disease for 3 months on hormonal therapy\n* Stable or unstable disease for at least 1 month after chemotherapy\n* No active brain metastases\n\n  * Brain metastases previously treated with definitive radiotherapy and/or surgical resection allowed\n* Hormone receptor status:\n\n  * Estrogen and progesterone receptor status known\n\nPhase II:\n\n* All Phase I criteria\n* HER2/neu overexpression (2+ or 3+) by immunohistochemistry\n\n  * Prior trastuzumab (Herceptin) allowed if disease still overexpresses HER2/neu\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Not specified\n\nPerformance status:\n\n* Karnofsky 70-100% OR\n* ECOG 0-2\n\nLife expectancy:\n\n* At least 3 months\n\nHematopoietic:\n\n* Granulocyte count at least 1,500/mm\\^3\n* Platelet count at least 50,000/mm\\^3\n* Hemoglobin at least 8 g/dL\n\nHepatic:\n\n* Bilirubin less than 1.5 times normal\n* SGOT less than 1.5 times normal\n\nRenal:\n\n* Creatinine no greater than 1.8 mg/dL\n* Creatinine clearance at least 60 mL/min\n* BUN no greater than 1.5 times normal\n\nCardiovascular:\n\n* No myocardial infarction within the past year\n* No prior myocardial infarction with coronary symptoms requiring medication and/or depressed left ventricular function (LVEF less than 50% by MUGA)\n* No angina or coronary symptoms requiring medication and/or with depressed left ventricular function (LVEF less than 50% by MUGA)\n* No congestive heart failure requiring medical management\n* LVEF at least 50% at rest by MUGA\n* No uncontrolled hypertension (i.e., systolic blood pressure \\[BP\\] \u2265 130 mm Hg or diastolic BP \u2265 80 mm Hg)\n\nPulmonary:\n\n* FEV1, DLCO, and FVC at least 50% predicted\n\nOther:\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* HIV negative\n* No other serious medical or psychiatric illness that would preclude study participation\n* No other prior or concurrent malignancy within the past 5 years except curatively treated squamous cell carcinoma in situ of the cervix, basal cell skin cancer, or any other curatively treated disease in complete remission\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* See Disease Characteristics\n* Prior trastuzumab allowed for phase I\n\nChemotherapy:\n\n* See Disease Characteristics\n* At least 4 weeks since prior chemotherapy\n\nEndocrine therapy:\n\n* See Disease Characteristics\n* Concurrent hormonal therapy for breast cancer must continue during study\n* No other concurrent hormonal therapy except steroids for adrenal failure, septic shock, or pulmonary toxicity or hormonal therapy for non-disease-related conditions (e.g., insulin for diabetes)\n\nRadiotherapy:\n\n* See Disease Characteristics\n\nSurgery:\n\n* See Disease Characteristics",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}